🏅 FDA Orphan Designation

Rylaze

asparaginase erwinia chrysanthemi (recombinant)-rywn

Manufacturer: Jazz Pharmaceuticals Ireland Limited

Indicated for:

Acute lymphoblastic leukemiaOrphanPlasmablastic lymphoma

FDA-Approved Indications (2)

Acute lymphoblastic leukemiaOrphan Designation

As a component of a multi-agent chemotherapeutic regimen for the treatment of acute lymphoblastic leukemia (ALL) and lymphoblastic lymphoma (LBL) in adult and pediatric patients 1 month or older who h…

Plasmablastic lymphoma

RYLAZE is indicated as a component of a multi-agent chemotherapeutic regimen for the treatment of lymphoblastic lymphoma (LBL) in adult and pediatric patients 1 month or older who have developed hyper…

Population: adult and pediatric patients 1 month or older

Indications & Usage

1 INDICATIONS AND USAGE RYLAZE is indicated as a component of a multi-agent chemotherapeutic regimen for the treatment of acute lymphoblastic leukemia (ALL) and lymphoblastic lymphoma (LBL) in adult and pediatric patients 1 month or older who have developed hypersensitivity to E. coli -derived asparaginase. RYLAZE is an asparagine specific enzyme indicated as a component of a multi-agent chemotherapeutic regimen for the treatment of acute lymphoblastic leukemia (ALL) and lymphoblastic lymphoma (LBL) in adult and pediatric patients 1 month or older who have developed hypersensitivity to E. coli -derived asparaginase. ( 1 )

Medical disclaimer: This information is for educational purposes only. Always consult a qualified healthcare provider before making treatment decisions. Data sourced from FDA and current as of our last update.